Tezampanel - Proniras
Alternative Names: LY 293558; NGX 424; PRN-001-01Latest Information Update: 14 Aug 2024
At a glance
- Originator Eli Lilly and Company
- Developer Indiana University School of Medicine; Proniras Corporation; Raptor Pharmaceutical Corp
- Class Analgesics; Antiepileptic drugs; Antimigraines; Antithrombotics; Drug withdrawal therapies; Isoquinolines; Tetrazoles
- Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Opioid-related disorders
- No development reported Seizures
- Discontinued Migraine; Neuromuscular disorders; Thrombosis
Most Recent Events
- 06 Aug 2024 Proniras Corporation plans a phase-I trial for Opioid-related disorders in October 2024 (IV), (NCT06538558)
- 01 Feb 2024 Proniras Corporation plans a phase I trial for Opioid related disorders (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Seizures in USA (Parenteral)